The FDA green­light­ed a high­ly an­tic­i­pat­ed pan­cre­at­ic can­cer treat­ment that has al­tered the prospects for pa­tients fac­ing the dead­ly dis­ease.

The agency on Wednes­day ap­proved...

Au­ro­ra Ther­a­peu­tics, the first com­pa­ny that fo­cused on cre­at­ing be­spoke gene edit­ing treat­ments, has laid off sev­er­al staff mem­bers and stopped its lead pro­gram.

The...

Hais­co Phar­ma­ceu­ti­cal li­cens­es in­flam­ma­to­ry dis­ease drug to Sen­tivera: The Chi­nese biotech is grant­i­ng ex-Chi­na rights for the un­named can­di­date to US start­up Sen­tivera, which...

Ake­so and its part­ner Sum­mit Ther­a­peu­tics pro­claimed on Tues­day that their high-pro­file PD-1xVEGF bis­pe­cif­ic hit a ma­jor Phase 3 mile­stone out­side of lung can­cer.

Ake­so...

Spyre Ther­a­peu­tics said Tues­day it is de­pri­or­i­tiz­ing its an­ti­body can­di­date for rheuma­toid arthri­tis (RA) af­ter the drug missed the biotech’s bar for suc­cess in a...